CAS: 4472-45-1; 4-Chloro-2,6-Dimethylpyrimidine

相似化合物

4595-69-1 55108-54-8 3435-25-4

上下游产品

CAS号6622-92-0 2,4-二甲基-6-羟基嘧啶 | CAS号1780-26-3 4,6-二氯-2-甲基嘧啶 | CAS号930-62-1 2,4-二甲基咪唑 | CAS号67-66-3 氯仿 | CAS号930-61-0 2.4-二甲基咪唑 | CAS号10025-87-3 三氯氧磷 | CAS号515-64-0 磺胺索嘧啶 | CAS号461-98-3 4-氨基-2,6-二甲基嘧啶 | CAS号1900-13-6 Nifurvidine | CAS号6622-92-0 2,4-二甲基-6-羟基嘧啶 | CAS号89808-18-4 4(1H)-Pyrimidin... | CAS号3163-31-3 N-[4-[[(2,6-dim... | CAS号14331-56-7 4-肼-2,6-二甲基嘧啶 | CAS号16879-44-0 4-iodo-2,6-dime... | CAS号73833-06-4 4-ethoxy-2,6-di... | CAS号64571-35-3 2,6-二甲基嘧啶-4-甲腈

4,6-二氯-2-甲基嘧啶置于四(三苯基膦)钯 Zinc Dibromide体系中,用 四氢呋喃,乙醚 作为反应溶剂,化学反应 9.0H,反应生成 2-氨基-4-氯-6-甲基嘧啶
参考文献: Pyrimidine Derivatives And Methods Of Treatment Related To The Use Thereof[fr] Derives De Pyrimidine Et Procedes De Traitement Lies A L'Utilisation De Ceux-Ci
标题: Pyrimidine Derivatives And Methods Of Treatment Related To The Use Thereof[fr] Derives De Pyrimidine Et Procedes De Traitement Lies A L'Utilisation De Ceux-Ci

专利信息

专利号:US-8895747-B2
优先权日:2009-07-27
标 题 :Method and substances for preparation of N-substituted pyridinium compounds
发明人：HEINDL DIETER; MAERZ HERIBERT; SCHMIDT AXEL
权利人:HEINDL DIETER; MAERZ HERIBERT; SCHMIDT AXEL; ROCHE DIAGNOSTICS OPERATIONS
摘要:Methods for the synthesis of N-substituted pyridinium compounds by using an N-heteroaryl substituted pyridinium salt (Zincke salt) and reacting it with a nucleophilic amine are provided. Novel purine-substituted pyridyl compounds, which may be useful reagents in the above reaction, are also disclosed.

专利号:US-6936600-B2
优先权日:1999-04-01
标题:Sorbitol dehrydrogenase inhibitors
发明人：CHU-MOYER MARGARET Y; MYLARI BANAVARA L; ZEMBROWSKI WILLIAM J
权利人:PFIZER
摘要:This invention is directed to sorbitol dehydrogenase inhibitory compounds of the formula I, n n nwherein R 1 , R 2 and R 3 are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, diabetic macroangiopathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefore at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an NHE-1 inhibitor and to methods of treating cardiomyopathy and other heart-related problems therewith. This invention is also directed to certain intermediates used in the synthesis of the compounds of formula I and to processes for preparing those intermediates.